Minerva Neurosciences, Inc $NERV Shares Purchased by Janus Henderson Group PLC

Janus Henderson Group PLC increased its position in shares of Minerva Neurosciences, Inc (NASDAQ:NERV) by 47,614.0% in the 1st quarter, Holdings Channel reports. The firm owned 4,294,259 shares of the biopharmaceutical company’s stock after purchasing an additional 4,285,259 shares during the period. Janus Henderson Group PLC owned 0.09% of Minerva Neurosciences worth $25,873,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. OMERS ADMINISTRATION Corp acquired a new stake in Minerva Neurosciences during the 1st quarter worth $62,000. Cannon Global Investment Management LLC acquired a new stake in shares of Minerva Neurosciences in the first quarter valued at about $107,000. Millennium Management LLC acquired a new stake in shares of Minerva Neurosciences in the fourth quarter valued at about $554,000. Logos Global Management LP acquired a new stake in shares of Minerva Neurosciences in the fourth quarter valued at about $13,310,000. Finally, Ally Bridge Group NY LLC purchased a new position in shares of Minerva Neurosciences in the fourth quarter worth about $6,655,000. 34.56% of the stock is owned by institutional investors and hedge funds.

Minerva Neurosciences Trading Down 0.3%

Shares of NERV opened at $3.97 on Tuesday. The company’s 50-day moving average price is $4.58 and its 200 day moving average price is $5.43. Minerva Neurosciences, Inc has a 12-month low of $1.76 and a 12-month high of $12.46. The firm has a market cap of $184.96 million, a P/E ratio of -0.14 and a beta of -0.16.

Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.04). Equities research analysts forecast that Minerva Neurosciences, Inc will post -0.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Citizens Jmp started coverage on shares of Minerva Neurosciences in a research report on Wednesday, April 15th. They set a “market outperform” rating and a $14.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Minerva Neurosciences in a report on Wednesday, June 24th. Finally, Wall Street Zen lowered shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $10.50.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.